A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence
The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
Despite years of active research, there are still no approved medications for the treatment of cocaine dependence. Modafinil is a glutamate-enhancing agent that blunts cocaine euphoria under controlled conditions, and the current study assessed whether modafinil would improve clinical outcome in cocaine-dependent patients receiving standardized psychosocial treatment. This was a randomized, double-blind, placebo-controlled trial conducted at a university outpatient center (from 2002 to 2003) on a consecutive sample of 62 (predominantly African American) cocaine-dependent patients (aged 25-63) free of significant medical and psychiatric conditions. After screening, eligible patients were randomized to a single morning dose of modafinil (400 mg), or matching placebo tablets, for 8 weeks while receiving manual-guided, twice-weekly cognitive behavioral therapy. The primary efficacy measure was cocaine abstinence based on urine benzoylecgonine levels. Secondary measures were craving, cocaine withdrawal, retention, and adverse events. Modafinil-treated patients provided significantly more BE-negative urine samples (p=0.03) over the 8-week trial when compared to placebos, and were more likely to achieve a protracted period (> or =3 weeks) of cocaine abstinence (p=0.05). There were no serious adverse events, and none of the patients failed to complete the study as a result of adverse events. This study provides preliminary evidence, which should be confirmed by a larger study, that modafinil improves clinical outcome when combined with psychosocial treatment for cocaine dependence.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with severe chronic health concerns tend to have a slower response to treatment with fewer days abstinent compared to patients without them.225”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [225]
In the citing paper
“A randomized placebo-controlled trial of modafinil (400mg/d) for CUD indicated significantly lower use compared to placebo, but no significant differences in craving or withdrawal (56), while a larger subsequent trial showed no differences in cocaine use, craving, withdrawal, retention, or abstinence even when accounting for dosage (57).”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [56]
In the citing paper
“Significantly greater abstinence compared to placebo, but no significant differences in craving or withdrawal.”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Dackis et al., 2005
In the citing paper
“Significantly greater abstinence compared to placebo, but no significant differences in craving or withdrawal.”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Dackis et al., 2005
In the citing paper
“Significantly greater abstinence compared to placebo, but no significant differences in craving or withdrawal.”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Dackis et al., 2005
Citations
Cites
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
(2001) · Statistics for Psychologists · doi:10.4324/9781410605542-11 · Cited by 6,877
The measurement of pessimism: the hopelessness scale
Beck, A. T., Weissman, A., Lester, D., & Trexler, L. (1974) · Journal of Consulting and Clinical Psychology · doi:10.1037/h0037562 · Cited by 5,494 · cited 3×
“…were assessed with the Addiction Severity Index (ASI) (McLellan et al, 1992), Hamilton Anxiety Scale (Ham A) (Hamilton, 1969), and Hamilton Depression Scale (Ham D) (Hamilton, 1967), Beck Depression Inventory (BDI) (Beck et al, 1974), and the Symptom Checklist 90 Revised (SCL90) (Derogatis, 1977).”
MethodThe fifth edition of the addiction severity index
McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,222
Self-citationSobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Diggle, P. J., Heagerty, P. J., Liang, K.-Y., & Zeger, S. L. (2002) · doi:10.1093/oso/9780198524847.001.0001 · Cited by 3,384
Sheehan, D., Lecrubier, Y., Harnett Sheehan, K., Janavs, J., Weiller, E., Keskiner, A., Schinka, J., Knapp, E., Sheehan, M., & Dunbar, G. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)83297-x · Cited by 2,149
[Drug addiction and drug abuse].
Feuerlein, W. (1969) · PubMed · Cited by 1,415
Research works printed but not linked: 4
- First MB, Spitzer RL, Gibbon M, Williams JBW (1996). Structured Clinical Interview for DSM-IV Axis I Disorders—Subject Edition (SCID-I/P, Version 2.0). Biometrics Research Department New York State Psychiatric Institute: New York.
- Kadden R, Carroll K, Donovan D, Cooney N, Monti P, Abrams D et al (1992). Cognitive-Behavioral Coping Skills Therapy Manual. US Government Printing Office: Washington, DC.
- Malcolm RJ, Donovan JL, DeVane CL, Elkashef A, Chiang N, Mojsiak J (2002). Influence of Modafinil, 400 or 800 mg/day on Subjective Effects of Intravenous Cocaine in Non-treatment Seeking Volunteers. College on Problems of Drug Dependence: Quebec City.
- Somoza E, Dyrenforth S, Goldsmith J, Mezinskis J, Cohen M (1995). In search of a Universal Drug Craving Scale. Annual Meeting of the American Psychiatric Association: Miami, FL.
Cited by
Items 301–391 of 391
Evidence-Based Practices for Co-occurring Addiction and Mental Illness
Yuodelis‐Flores, C., Iles-Shih, M., & Ries, R. K. (2022) · Springer eBooks · doi:10.1007/978-3-031-10239-4_25 · Cited by 3
Turpin, M. A. C., Rowland, K. C., Anugwom, C., Arocha, M., Carona, A., Gonzalez, B. I., Iskander, G., Snyder, S., Wilson, K., Kaye, A. D., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98814-8.00027-5 · Cited by 6
Disorders due to Substance Use: Stimulants
Sevarino, K. A., & Farrell, M. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_26 · Cited by 4
Sinatora, A. B., Chiloff, D. M., Santos, J. P. M., Xu, K. Y., Tardelli, V. S., & Fidalgo, T. M. (2025) · Substance Use & Addiction Journal · doi:10.1177/29767342251326374 · Cited by 4
Agonist treatment for stimulant abuse and dependence
Herin, D. V., & Grabowski, J. G. (2007) · Elsevier eBooks · doi:10.1016/b978-008044927-2/50057-2 · Cited by 2
L'addiction à la cocaïne : de l'épidémiologie aux approches thérapeutiques
Karila, L., Lafaye, G., & Reynaud, M. (2009) · L information psychiatrique · doi:10.1684/ipe.2009.0521 · Cited by 5
“Aucun effet secondaire spécifique n ’ a été relevé [48].”
Pharmacotherapy of Alcohol and Drug Dependence
Swift, R. M., & Aoun, E. G. (2014) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-014-0029-7 · Cited by 2
“A more recent RCT in 210 cocainedependent subjects failed to reproduce these results [102].”
ResultNauka o uzależnieniach. Od neurobiologii do skutecznych metod leczenia
Erickson, C. K. (2010) · Wydawnictwa Uniwersytetu Warszawskiego eBooks · doi:10.31338/uw.9788323506621 · Cited by 3
Nauka o uzależnieniach. Od neurobiologii do skutecznych metod leczenia
Erickson, C. K. (2010) · Wydawnictwa Uniwersytetu Warszawskiego eBooks · doi:10.31338/uw.9788323527190 · Cited by 9
Quednow, B. B., & Herdener, M. (2018) · Elsevier eBooks · doi:10.1016/b978-3-437-23021-9.00008-4 · Cited by 2
Ethical and policy issues in the translation of genetic and neuroscience research on addiction
Carter, A., & Hall, W. (2007) · Elsevier eBooks · doi:10.1016/b978-008044927-2/50070-5 · Cited by 2
Pharmacological Interventions in Gambling Disorder
Medeiros, G. C., & Grant, J. E. (2019) · Springer eBooks · doi:10.1007/978-3-030-03060-5_8 · Cited by 2
Pharmacological management of psychoactive substance withdrawal syndrome
Fluyau, D., Cook, S., Chima, A., Kailasam, V. K., & Revadigar, N. (2021) · Drugs & Therapy Perspectives · doi:10.1007/s40267-021-00874-7 · Cited by 2
Chest Tightness and Palpitations Associated With Modafinil and Consumption of Free Glutamate
MORGAN, P. T., & Malison, R. T. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07040717 · Cited by 2
Normalizing Effects of Modafinil on Cocaine-Induced Sleep Abnormalities
Dackis, C. A., & O’Brien, C. P. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09111613 · Cited by 2
Self-citationDermatis, H., & Galanter, M. S. (2007) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.5.2.foc141 · Cited by 2
[Iatrogenic Cushing's syndrome and cortico-dependent gout. (Presentation of a case)].
Errazti, A. R., Pombo, J. L. H., Casado, M. J., & Jl, R.-M. (1965) · PubMed · Cited by 2
Dopamine Receptors: Neurotherapeutic Targets for Substance Use Disorders
Nilson, A. N., Felsing, D. E., & Allen, J. (2022) · Wiley eBooks · doi:10.1002/9781119564782.ch19 · Cited by 3
The Effect of Modafinil Treatment on Cravings in Methamphetamine Use Disorder
Bardakçı, M. R., Yazıcı, A. B., Bardakçı, Ş., & Yazıcı, E. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2446468 · Cited by 2
“In studies on methamphetamine use disorder (Anderson et al. 2012) and cocaine use disorder, similar results were obtained for modafinil at different doses (Dackis et al. 2005; Hart et al. 2008).”
Pareek, T., Vergis, J. M., Zhang, X., Platt, D. M., Grant, K. A., McCullumsmith, R., Gisabella, B., O'Donovan, S. M., & Pantazopoulos, H. (2026) · Scientific Reports · doi:10.1038/s41598-026-51816-0 · Cited by 2
Elkashef, A. M., & Montoya, I. D. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3375-0_8 · Cited by 1
Xi, Z. (2012) · InTech eBooks · doi:10.5772/50303 · Cited by 1
“The first randomized, double-blind clinical trial involved 62 cocaine-dependent outpatients who received either a single dose of modafinil or placebo daily for 8 weeks (Dackis et al., 2005).”
Usage élargi du modafinil : quel risque addictif ?
Eysseric, H., Vincent, F., Mallaret, M., Barjhoux, C.-E., & Barret, L. G. (2006) · Annales de Toxicologie Analytique · doi:10.1051/ata:2006028 · Cited by 1
Pharmacotherapy for Cocaine Use Disorders
Quednow, B. B., Engeli, E., & Herdener, M. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_457-1 · Cited by 1
Daamen, A. P., Penning, R., Brunt, T. M., & Verster, J. C. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3375-0_12 · Cited by 1
Hua, C. (2023) · Frontiers in clinical drug research. CNS and neurological disorders · doi:10.2174/9789815123319123110004 · Cited by 1
Quednow, B. B., & Herdener, M. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21074-7.00011-3 · Cited by 3
Treating Cocaine Dependency with Psychopharmacotherapy and Behavioral Therapy
Liebman, R. (2014) · Chapman University Digital Commons (Chapman University) · Cited by 1
Preclinical Development and Clinical Implementation of Treatments for Substance Abuse Disorders
Pechnick, R. N., Glasner, S. V., Hrymoc, M., & Wilkins, J. N. (2007) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.5.2.foc151 · Cited by 1
Drug Abuse, Dependency, and Withdrawal
Kay, A. L., Stober, K. R., Serota, R. D., & Weinstein, S. P. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1703-7.10060-x · Cited by 1
Integrative Approach to Stimulant-Use Disorder
Mitton, A. G., & Mooney, L. J. (2018) · Oxford University Press eBooks · doi:10.1093/med/9780190275334.003.0007 · Cited by 1
Modafinil in the treatment of selected mental disorders
Dyrda, W., Smułek, D., Wichniak, A., & III Klinika Psychiatryczna i Ośrodek Medycyny Snu, I. P. I. N. W. W. (2021) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2021.0022 · Cited by 1
ADHD and Co-Occurring Substance Use Disorders
Hernández, M., Dambreville, N., & LEVIN, F. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-84834-7_2 · Cited by 1
Soyka, M. (2018) · Elsevier eBooks · doi:10.1016/b978-3-437-23021-9.00018-7 · Cited by 1
Sevarino, K. A., & Shelby, B. C. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch80 · Cited by 1
Investigating the Effects of Novel Kappa Opioid Receptor Agonists on the Dopamine Transporter
Simonson, B. (2011) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.16985389.v1 · Cited by 3
“Modafinil has shown promise as a pharmacotherapeutic for drug abuse by decreasing cravings for cocaine and increasing the length of abstinence (Dackis et al. 2005; Dackis and O'Brien 2006).”
BackgroundPharmacological Therapeutics for Detoxification in Addictive Disorders
Kobeissy, F. H., Braga, C. F., Graham, N. A., & Gold, M. S. (2010) · Wiley eBooks · doi:10.1002/9780470710449.ch32 · Cited by 1
Newman, A. H., & Rothman, R. B. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00167-x · Cited by 3
Reply to Modafinil: Mischaracterization
Biederman, J. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0624c · Cited by 1
Niesink, R. J. M. (2008) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-6554-8_10 · Cited by 1
Circuit breakers for addiction
Foy, A. (2007) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2007.01350.x · Cited by 1
Petropoulos, A. (2010) · QSpace (Queen's University Library) · Cited by 2
Pharmacotherapy of Cocaine Addiction
Elkashef, A. M., & Vocci, F. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0338-9_50 · Cited by 2
“[17] A double-blind, placebo-controlled trial of modafinil for cocaine dependence.”
BackgroundCentral nervous system stimulants and drugs that suppress appetite
Sequeira, R. P. (2008) · Side effects of drugs annual · doi:10.1016/s0378-6080(08)00001-9 · Cited by 1
Modafinil for excessive daytime sleepiness
Mathew, M. E., Biswas, T., Fahad, S., & Patnaik, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010843 · Cited by 1
RetractedRecent Advances in Drug Development
Vocci, F. J. (2014) · Springer eBooks · doi:10.1007/978-88-470-5322-9_32
Evaluation of Modafinil in Preclinical Behavioral Assays of Abuse Liability
Quisenberry, A. J. (2013) · ScholarWorks - WMU (Western Michigan University)
Quisenberry, A. J., Watkins, E. E., Harvey, E. L., & Walters, J. L. (2013)
Practical Pharmacological Maintenance Treatment of Bipolar Disorder
Swann, A. C. (2010) · Wiley eBooks · doi:10.1002/9780470661277.ch24
White, S. (2013) · ScholarlyCommons (University of Pennsylvania)
Belemmeringen voor methadonbehandeling in Amsterdam
Witteveen, E., & van Santen, G. (2011) · Verslaving · doi:10.1007/s12501-011-0008-6
Pharmacological Therapeutics for Relapse Reduction in Addictive Disorders
Merlo, L. J., Blumenthal, K. G., Campbell, K. M., Omli, M. R., & Gold, M. S. (2010) · Wiley eBooks · doi:10.1002/9780470710449.ch33
Optimizing anesthesia techniques in the ambulatory setting
Galvin, E. M. (2007) · RePub (Erasmus University Rotterdam)
Evidence-Based Practices for Co-occurring Chemical Dependency and Mental Illness
Yuodelis‐Flores, C., Ries, R. K., & Bennett, W. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3149-7_23
Boosting impulse control in addiction. Pharmacological neuroimaging studies
Schmaal, L. (2013) · UvA-DARE (University of Amsterdam)
Consumo adictivo de sustancias psicoactivas
Martínez‐Gras, I., Martı́nez-Raga, J., Arriero, M. Á. J., & Rubio, G. (2011) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(11)70179-2
A Different Mechanism to Understand Activation/Sedation Side Effects of Ziprasidone
Brophy, M. H. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0624f
The Role of Self-efficacy in Cocaine Abstinence
Sylvest, C. E. (2009) · doi:10.13021/mars/6235 · Cited by 1
Modafinil for excessive daytime sleepiness
Mathew, M. E., Biswas, T., Fahad, S., & Patnaik, M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010843.pub2
N orm a liz in g E ffe c ts of M oda fi n il on S le e p in C h ron ic C oc a in e U se rs
MORGAN, P. T., & Malison, R. T. (2010)
Brodie, J. D., Case, B. G., Figueroa, E., Dewey, S. L., Robinson, J. A., WANDERLING, J. A., & LASKA, E. M. (2009)
Psychische Störungen infolge anderer psychotroper Substanzen
Soyka, M., & Stohler, R. (1996) · Elsevier eBooks · doi:10.1016/b978-343722880-3.50019-6
Targeting the trace amine-associated receptor 1 in psychomotor stimulant addiction.
Pei, Y. (2016) · UC Research Repository (University of Canterbury) · doi:10.26021/8251
“Clinical trials reported limited efficacy of modafinil in cocaine users, preferentially in non-alcohol dependent males (Anderson et al., 2009, Dackis et al., 2012), and in METH users 26 without other substance dependence and those attending counselling (Shearer et al., 2009).”
BackgroundBipolar Disorder With Comorbid Alcohol or Substance Abuse
Goldberg, J. F. (2007)
Treatment of Methamphetamine withdrawal in trauma patients
Phillips, B., Snyder, S., Safa, H., Wu, J., Shahid, M. M., Turco, L. M., Schroeder, A., Weber, W., & Asensio, J. A. (2017) · Integrative Clinical Medicine · doi:10.15761/icm.1000101
“Modafinil may also decrease craving for methamphetamine while improving overall cognition [13] and is currently being investigated in a number of clinical trials.”
BackgroundInfluentialNuijten, M. (2017) · Leiden Repository (Leiden University) · Cited by 1
Psychische Störungen infolge anderer psychotroper Substanzen
Soyka, M. (2017) · Elsevier eBooks · doi:10.1016/b978-3-437-22881-0.00017-4
Neuroplasticity-Targeted Therapy Alleviates Severe Addiction
Famitafreshi, H., & Karimian, M. (2019) · doi:10.37532/1758-2008.2019.9(4).592 · Cited by 1
La dipendenza da cocaina: verso un'integrazione delle cure
Radolovic, D. (2021) · PNEI REVIEW · doi:10.3280/pnei2021-001004
Briand, L. A. (2007) · Deep Blue (University of Michigan)
(2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-387-25733-0_14
Howell, L. L., & Kimmel, H. L. (2007) · Wiley eBooks · doi:10.1002/9780470101001.hcn038
Current awareness in human psychopharmacology
(2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.636
Reply to A Different Mechanism to Understand Activation/Sedation Side Effects of Ziprasidone
Stahl, S. M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0624g
Nader, M. A. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727378029.793553498
L'addiction à la cocaïne : de l'épidémiologie aux approches thérapeutiques
Karila, L., Lafaye, G., & Reynaud, M. (2009) · L information psychiatrique · doi:10.3917/inpsy.8507.0647
Boateng, C. A., Schweppe, C. A., & Newman, A. H. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.10979-5
The in vivo Use of Dopamine Binding Aptamers in a Mouse Model of Dopamine Dysregulation
Ventura, K. (2016) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2016-11720
Disorders Due to Substance Use: Stimulants
Sevarino, K. A., & Farrell, M. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_26-1 · Cited by 1
Reinforcing Effects of the Novel Dopamine Transport Inhibitors Jjc8-088 and Jjc8-091 in MonkeysPreprint
Allen, M. I., Rahimi, O., Johnson, B., Cao, J., Newman, A. H., & Nader, M. A. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4773961
Clinical and Pharmacological Characteristics of the Drug Modafinil
Кевра, М. К., Gavrilenko, L. N., & Popov, A. S. (2023) · Рецепт · doi:10.34883/pi.2023.26.6.017
Chapter 54. Treatment of Substance Use Disorders
Sherman, B. J., Hartwell, K. J., McRae‐Clark, A. L., Herron, A., & Brady, K. T. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as54
Chapter 45. Psychostimulants and Wakefulness-Promoting Agents
DeBattista, C. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as45
Graddy, R., & Rastegar, D. A. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197796207.003.0008
Karila, L., Lépine, J., Coscas, S., Beck, F., & Reynaud, M. (2009) · Elsevier eBooks · doi:10.1016/b978-2-294-70316-4.00013-8
Kokain, Amphetamin und andere Stimulanzien
Koopmann, A., Fehr, C., & Kiefer, F. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_70
A Case Report on Modafinil Dependence
D’Souza, P. R., & Mascarenhas, J. J. (2019) · Galore International Journal of Health Sciences and Research · doi:10.52403/gijhsr.20190302 · Cited by 1
Paterson, C., Parkhouse, T., Burke, C., Halicka, M., Palmer, J. C., Gabr, H., Wilson, R., Webster, K. E., Spiga, F., Dawson, S., et al. (2025) · medRxiv · doi:10.64898/2025.12.10.25341965
Paterson, C. A., Parkhouse, T., Burke, C., Halicka, M., Palmer, J. C., Gabr, H., Wilson, R. J., Webster, K. E., Spiga, F., Dawson, S., et al. (2026) · Addiction · doi:10.1111/add.70486 · Cited by 4
The use of Drosophila to study sleep impairments in stimulant use disorder
Miles, M., Karatas, M., & Rothenfluh, A. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1913395
“…decrease in stimulant self-administration and increase in treatment retention in stimulant users without other ongoing substance dependencies (Dackis et al., 2005; McGregor et al., 2008; Anderson et al., 2009; Morgan et al., 2010), though evidence is mixed for its efficacy among…”
Metadata
- Authors
- Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Dackis, Charles A
- Venue
- Neuropsychopharmacology
- Published
- 2004-11-03
- Volume
- 30
- Issue
- 1
- Pages
- 205-211
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1966136869
- Cited by
- 391
- References
- 44
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 9 · 2023: 8 · 2022: 9 · 2021: 13 · 2020: 2 · 2019: 10 · 2018: 6 · 2017: 8 · 2016: 21 · 2015: 17 · 2014: 21 · 2013: 21 · 2012: 26
- FWCI
- 19.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p60da005186-25)
- National Institute on Drug Abuse (DA P60-05186, DA P50-12756, P50DA012756)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- modafinil, cocaine dependence, cocaine abstinence, cognitive behavioral therapy, psychosocial interventions, cocaine craving, cocaine withdrawal, medication-assisted treatment, African American patients
- MeSH terms
- Modafinil, Adult, Central Nervous System Stimulants, Benzhydryl Compounds, Double-Blind Method, Female, Humans, Male, Middle Aged, Patient Compliance, Psychiatric Status Rating Scales, Substance Withdrawal Syndrome, Treatment Outcome, Sample Size, Cocaine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.